{"id":556645,"date":"2026-06-04T22:45:51","date_gmt":"2026-06-04T20:45:51","guid":{"rendered":"https:\/\/medizinonline.com\/?p=556645"},"modified":"2026-06-01T11:05:22","modified_gmt":"2026-06-01T09:05:22","slug":"destiny-breast11-t-dxd-neoadiuvante-senza-antracicline","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/it\/destiny-breast11-t-dxd-neoadiuvante-senza-antracicline\/","title":{"rendered":"DESTINY-Breast11 – T-DXd neoadiuvante senza antracicline"},"content":{"rendered":"\n

Lo studio di fase III DESTINY-Breast11 dimostra che il trastuzumab deruxtecan neoadiuvante (T-DXd) potrebbe fornire un’opzione di trattamento senza antracicline per il carcinoma mammario precoce HER2-positivo. I risultati suggeriscono un’alternativa efficace e meglio tollerata ai regimi standard contenenti antracicline. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Accedi<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Lo studio di fase III DESTINY-Breast11 dimostra che il trastuzumab deruxtecan neoadiuvante (T-DXd) potrebbe fornire un’opzione di trattamento senza antracicline per il carcinoma mammario precoce HER2-positivo. I risultati suggeriscono un’alternativa……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Accedi<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":556646,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancro al seno precoce HER2+","footnotes":""},"category":[11550,11519,11409,11376,11515],"tags":[92374,92381,13612,92370,92369,92375,92396,90862,92398,92394,92372,92367,92392,92382,16482,92391,92387,92376,92395,92390,92393,13616,92389,92384,92378,92397,54739,92380,23652,55537,92368,92377,72794,90863,92388,92373,92379,92383,92386,92385,92371],"powerkit_post_featured":[],"class_list":["post-556645","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-it","category-formazione-continua","category-ginecologia-it","category-oncologia-it","category-studi","tag-anticorpi-mirati-a-her2","tag-approccio-senza-antracicline","tag-cancro-al-seno","tag-cancro-al-seno-adc","tag-cancro-al-seno-precoce-her2-positivo","tag-carcinoma-mammario-her2-positivo","tag-cardiotossicita-antracicline","tag-coniugato-anticorpo-farmaco-2","tag-consenso-di-san-gallo","tag-ddac-thp","tag-destino-seno03","tag-destino-seno11","tag-efficacia-di-t-dxd","tag-efs","tag-her2-it","tag-metastasi-cerebrali-cancro-al-seno","tag-metastasi-leptomeningee","tag-monoterapia-con-t-dxd","tag-neutropenia-grave","tag-oncologia-svizzera","tag-paclitaxel-piu-doppio-blocco-her2","tag-pfs-it","tag-regime-di-trattamento-con-antracicline-a-dose-ridotta","tag-regime-di-trattamento-senza-antracicline","tag-remissione-patologica-completa","tag-sicurezza-t-dxd","tag-sopravvivenza-globale","tag-sopravvivenza-libera-da-eventi","tag-sopravvivenza-libera-da-progressione","tag-t-dm1-it","tag-t-dxd","tag-t-dxd-neoadiuvante","tag-tasso-di-pcr","tag-terapia-adc","tag-terapia-contenente-antracicline-t-dxd","tag-terapia-mirata-a-her2","tag-terapia-neoadiuvante-her2-positiva","tag-terapia-thp","tag-tossicita-cardiaca","tag-tossicita-ematologica","tag-trastuzumab-deruxtecan","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-04 19:03:58","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":556714,"slug":"destiny-breast11-t-dxd-neoadjuvante-sem-antraciclinas","post_title":"DESTINY-Breast11 - T-DXd neoadjuvante sem antraciclinas","href":"https:\/\/medizinonline.com\/pt-pt\/destiny-breast11-t-dxd-neoadjuvante-sem-antraciclinas\/"},"es_ES":{"locale":"es_ES","id":556758,"slug":"destiny-breast11-t-dxd-neoadyuvante-sin-antraciclinas","post_title":"DESTINY-Breast11 - T-DXd neoadyuvante sin antraciclinas","href":"https:\/\/medizinonline.com\/es\/destiny-breast11-t-dxd-neoadyuvante-sin-antraciclinas\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/556645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=556645"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/556645\/revisions"}],"predecessor-version":[{"id":556647,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/556645\/revisions\/556647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media\/556646"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=556645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/category?post=556645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/tags?post=556645"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/powerkit_post_featured?post=556645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}